Roche moves into automated insulin delivery with Diabeloop tie-up

Roche announced Friday that it is collaborating with Diabeloop, a specialist in artificial intelligence (AI)-driven technologies for personalised diabetes management, to bring to market hybrid closed-loop systems for patients with diabetes. The partnership marks Roche's debut in automated insulin delivery, something it describes as a "milestone" in its strategy of integrated personalised diabetes management.

Marcel Gmuender, global head of Roche Diabetes Care, noted that Diabeloop's "unique" technology is based on a self-learning algorithm, adding "we are convinced that the potential of the hybrid closed-loop systems will contribute to a more efficient and personalised approach of diabetes management." Financial terms of the deal were not disclosed.

Diabeloop obtained CE marking in 2018 for DBLG1, a self-learning algorithm to automate and personalise the treatment of type 1 diabetes. Linked to a continuous blood glucose monitoring system and insulin patch pump, the company says DBLG1 can "predict glucose levels and command the insulin pump at an optimal rate." More recently, Diabeloop also gained the CE mark for its DBL-hu automated management solution, which is designed to improve glycaemic control in those with highly unstable type 1 diabetes.

Roche diabetes care offerings include Accu-Chek glucose monitoring and insulin delivery systems. On its website, the company said its "newest addition" is the tubeless Accu-Chek Solo micropump system with open bolus advice for coupling with an approved flash or continuous glucose monitoring device. This system received the CE mark in 2018, with Roche noting at the time that it integrates with the company's "digital health solutions, contributing to more effective and personalised diabetes management."

For realted analysis, read Wider View: Better late than never for Roche to loop into AID.

To ensure you don't miss other Top Stories like these and news on key medtech industry developments, sign up for our free daily e-newsletter here.  

Did you like this article?